What Is Cerebrolysin?
Cerebrolysin is a proprietary mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine (pig) brain protein, marketed as a neurotrophic/neuroprotective injectable drug. It is given intravenously or intramuscularly and is widely used for acute ischaemic stroke, vascular dementia, Alzheimer’s disease, and traumatic brain injury in Russia, Eastern Europe, China, and other parts of Asia, where it is a prescription medicine. It is not approved by the US FDA and is not a dietary supplement. Of the compounds in this section it has an unusually large human trial base, though the quality and interpretation of that evidence remain debated.
Evidence
Cerebrolysin has been evaluated in multiple randomised controlled trials and in Cochrane systematic reviews, which is what distinguishes it from most research peptides. A 2020 Cochrane review of Cerebrolysin for acute ischaemic stroke concluded that moderate-certainty evidence indicates it probably has no beneficial effect on all-cause death, and flagged a potential increase in non-fatal serious adverse events 1Reference 1Systematic reviewCerebrolysin for acute ischaemic stroke — systematic review (Cochrane)View study →. For dementia the picture is more mixed: a 2013 Cochrane review of six randomised trials (597 participants) in vascular dementia reported a beneficial effect on cognitive measures (MMSE and ADAS-cog+) and on global clinical response, but judged the evidence insufficient to recommend routine use given the small number of trials 2Reference 2Systematic reviewCerebrolysin for vascular dementia — systematic review (Cochrane)View study →. Some newer meta-analyses of stroke trials report modest neurological improvement, so the overall picture is genuinely unsettled rather than clearly positive. Much of the supporting literature originates from a small number of countries and is subject to concerns about risk of bias, which is why even the favourable dementia findings are held as promising-but-unproven 1,2Reference 1Systematic reviewCerebrolysin for acute ischaemic stroke — systematic review (Cochrane)View study →Reference 2Systematic reviewCerebrolysin for vascular dementia — systematic review (Cochrane)View study →.
Dosage & Safety
Cerebrolysin is administered by a clinician as an intravenous or intramuscular injection; trial regimens have typically used courses on the order of 10–50 mL/day for several weeks, but this is a physician-administered prescription drug and no dosing guidance is given here. The 2020 Cochrane stroke review specifically flagged a possible increase in non-fatal serious adverse events, so a benign safety profile should not be assumed 1Reference 1Systematic reviewCerebrolysin for acute ischaemic stroke — systematic review (Cochrane)View study →. Cerebrolysin is not FDA-approved and is not an approved dietary supplement in the US. Because it is derived from animal (porcine) brain tissue, it also raises theoretical concerns that do not apply to synthetic peptides. Drug interactions, long-term safety, and pregnancy/lactation safety are not established in this pass. This entry is informational only.
References
- Ziganshina LE, Abakumova T, Hoyle CHV. (2020). Cerebrolysin for acute ischaemic stroke — systematic review (Cochrane). Cochrane Database Syst Rev. https://pubmed.ncbi.nlm.nih.gov/32662068/
- Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. (2013). Cerebrolysin for vascular dementia — systematic review (Cochrane). Cochrane Database Syst Rev. https://pubmed.ncbi.nlm.nih.gov/23440834/